UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~March~~June 3130, 2012

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _____________to _____________

NERIUM BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Canada	000-54051	14-1987900
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

11467 Huebner Road, Suite 175

San Antonio, Texas, 78230

(Address of Principal Executive Office) (Zip Code)

(210) 822-7908

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer o		Accelerated filer o
Non-accelerated filer o		Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

The number of shares outstanding of the Registrant’s common stock as of ~~May~~August 1427, 2012 is 3335,~~808~~156,~~176~~414.

NERIUM BIOTECHNOLOGY, INC.

INDEX TO FORM 10-Q

FOR THE THREE- AND SIX MONTH ~~PERIOD~~PERIODS ENDED ~~MARCH~~JUNE 3130, 2012

(EXPRESSED IN UNITED STATES FUNDS)

Part I	FINANCIAL INFORMATION	~~FINANCIAL INFORMATION~~
Item 1	Interim Condensed Consolidated Financial Statements (Unaudited)	~~Interim Condensed Consolidated Financial Statements (Unaudited)~~3	3
	Interim Condensed Consolidated Balance Sheets (Unaudited)	~~Interim Condensed Consolidated Balance Sheets (Unaudited)~~
		Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
	Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
		Interim Condensed Consolidated Statements of Changes in Stockholder’ Equity (Unaudited)
	Interim Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)
	Interim Condensed Consolidated Statements of Cash Flows (Unaudited)	~~Interim Condensed Consolidated Statements of Cash Flows (Unaudited)~~
	Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)	~~Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)~~
Item 2	Management’s Interim Discussion and Analysis of Financial Condition and Results of Operations	~~Management’s Interim Discussion and Analysis of Financial Condition and Results of Operations~~19	18
Item 3	Quantitative and Qualitative Disclosures About Market Risk	~~Quantitative and Qualitative Disclosures About Market Risk~~24
Item 4	Controls and Procedures	~~Controls and Procedures~~25	22
Part II	OTHER INFORMATION	~~OTHER INFORMATION~~
Item 1	Legal proceedings	~~Legal proceedings~~26	23
Item 1A	Risk Factors	~~Risk Factors~~26	23
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	~~Unregistered Sales of Equity Securities and Use of Proceeds~~29	26
Item 3	Defaults upon Senior Securities	~~Defaults upon Senior Securities~~29	26
Item 4	Mine Safety Disclosures	~~Mine Safety Disclosures~~29
Item 5	Other information	~~Other information~~30	26
Item 6	Exhibits	~~Exhibits~~31	27

Index

Nerium Biotechnology, Inc.

Part I

Item 1. Financial Statements

Interim Condensed Consolidated Balance Sheets

(Unaudited)

	March 31 2012			December 31 2011
	June 30 2012			December 31 2011
Assets
Current assets
Cash and cash equivalents	$	~~666~~622,~~735~~789		$	217,034
Accounts receivable		62,~~282~~019			3,934
Accounts receivable from related party (note 8)		20,000			-
Accounts receivable from related party (note 9)		525,100			-
Inventory (note 4)		~~367~~510,~~883~~557			368,696
Prepaid expenses and deposits		~~170~~402,~~734~~486			89,481
Total current assets		12,~~231~~062,~~634~~951			679,145
Prepaid expenses relating to patents		7376,~~096~~301			68,507
Equipment, net (note 5)		200,297			213,851
Deposit for equipment (note 10)		75,000			-
Total assets	$	1,505,027		$	961,503
Equipment, net (note 5)		203,105			213,851
Equity investment (note 6)		226,340			-
Total assets	$	2,643,697		$	961,503
Liabilities
Current liabilities
Accounts payable		~~119~~154,~~590~~044			-
Accrued liabilities		~~167~~86,~~237~~001			266,081
Employee related payables		22,325			-
Advances (note 7(b)(xvi))		100,000			-
Loan from related party (note 8)		80,000			-
Employee related payables		14,462			-
Advance from related party (note 8)		27,150			3,914
Loan from related party (note 9)		71,000			-
Customer deposits		515,000			75,000
Advance from related party		-			3,914
Total liabilities		931,302			344,995
Customer deposits		160,000			75,000
Income taxes payable (note 14)		240,000			-
Total liabilities		825,507			344,995
Stockholders’ Equity
Preferred stock, no-par value, unlimited, none issued and outstanding		-			-
Common stock, no-par value, unlimited authorized, 33,607,176 (December 31, 2011 – 32,617,105) shares issued and outstanding (note 6)		7,352,410			7,077,077
Common stock, no-par value, unlimited authorized, 33,808,176 (December 31, 2011 – 32,617,105) shares issued and outstanding (note 7)		7,553,410			7,077,077
Additional paid in capital		3,~~313~~722,~~016~~712			2,082,988
Accumulated comprehensive (loss) income		(2,~~690~~687	)		2,922
Accumulated deficit		(109,~~078~~444,~~107~~198	)		(8,535,754	)
Nerium Biotechnology, Inc. Stockholders’ equity		~~584~~1,~~629~~829,237			627,233
Non-controlling interests		(1011,~~904~~047	)		(10,725	)
Total stockholders’ equity		~~573~~1,~~725~~818,190			616,508
Total liabilities and equity	$	12,~~505~~643,~~027~~697		$	961,503
Going Concern (note 2)
Going Concern and Economic Dependence (note 2)
Commitments (note 9)
Commitments (note 10)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Index

Nerium Biotechnology, Inc.

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

For the three and six month periods ended June 30, 2012

(Unaudited)

	March 31 2012			March 31 2011
		Three months ended June 30						Six months ended June 30
Revenue
		2012			2011			2012			2011
Sales (note 8)	$	687,734		$	122,542
Revenue
Other		1,559			2,243
Sales (note 9)	$	2,478,932		$	103,118		$	3,166,666		$	225,660
		689,293			124,785
Other		3,825			1,098			5,384			3,341
Cost of Sales		469,900			38,935
		2,482,757			104,216			3,172,050			229,001
Gross profit		219,393			85,850
Cost of sales (note 10)		1,457,094			19,924			1,926,994			58,859
Expenses
Gross profit		1,025,663			84,292			1,245,056			170,142
General and administrative (note 8)		389,468			229,673
Operating expenses
Research and development		64,856			62,138
General and administrative (note 9)		331,170			366,438			720,638			596,111
Stock-based compensation (note 7)		1,298,290			-
Research and development		32,788			226,034			97,644			288,172
Depreciation		9,311			10,490
Stock-based compensation (note 8)		84,365			504,043			1,382,655			504,043
Foreign exchange loss		-			2,739
Depreciation		9,851			8,063			19,162			18,553
		1,761,925			305,040
Foreign exchange (gain) loss		(296	)		2,023			(296	)		4,762
Net loss for the period		(1,542,532	)		(219,190	)
Total operating expenses		457,878			1,106,601			2,219,803			1,411,641
Exchange difference on translating foreign operations		(5,612	)		6,683
Income (loss) from operations		567,785			(1,022,309	)		(974,747	)		(1,241,499	)
Comprehensive loss for the period		(1,548,144	)		(212,507	)
Earnings from equity investment		305,981			-			305,981			-
Loss attributable to non-controlling interest		179			145
Net income (loss) before income taxes		873,766			-			(668,766	)		-
Loss attributable to controlling interest	$	(1,547,965	)	$	(212,362	)
Provision for income taxes (note 14)		240,000			-			240,000			-
Basic and diluted loss per common share	$	(0.05	)	$	(0.01	)
Net income (loss) for the period		633,766			(1,022,309	)		(908,766	)		(1,241,499	)
Weighted-average common shares outstanding- basic and diluted		32,638,865			31,551,334
Exchange difference on translating foreign operations		3			606			(5,609	)		7,289
Comprehensive income (loss) for the period		633,769			(1,021,703	)		(914,375	)		(1,234,210	)
Loss attributable to non-controlling interest		(143	)		(141	)		(322	)		(286	)
Income (loss) attributable to controlling interest	$	633,912		$	(1,021,562	)	$	(914,053	)	$	(1,233,924	)
Basic earnings (loss) per common share	$	0.02		$	(0.03	)	$	(0.03	)	$	(0.04	)
Diluted earnings (loss) per common share	$	0.02		$	(0.03	)	$	(0.03	)	$	(0.04	)
Weighted-average common shares outstanding- basic		33,741,813			32,076,882			33,190,339			31,815,560
Weighted-average common shares outstanding- diluted		35,492,813			32,076,882			33,190,339			31,815,560

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Index

Nerium Biotechnology, Inc.

Interim Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the ~~three~~six month period ended ~~March~~June 3130, 2012

(Unaudited)

	Common Stock					Preferred Stock						Shares to be		Additional Paid-in			Accumulated Other Comprehensive			Non- Controlling			Accumulated			Total Stockholders’ Equity
														Accumulated
	Shares			Amount		Shares			Amount			Issued		Capital			Loss			Interest			Deficit
												Additional		Other			Non-						Total
At December 31, 2010		31,544,681		$	5,814,538		-		$	-		$	-	$	1,410,215		$	(3,871	)	$	(10,140	)	$	(6,671,273	)	$	539,469
	Common Stock					Preferred Stock						Paid-in		Comprehensive			Controlling			Accumulated			Stockholders’
Preference shares issued (note 6(b)(ii) and( viii))		-			-		750,000			750,000			-		-			-			-			-			750,000
	Shares			Amount		Shares			Amount			Capital		Income (Loss)			Interest			Deficit			Equity
Issued on private placements (note 6(b)(i))		199,583			299,374		-			-			-		-			-			-			-			299,374
At December 31, 2010		31,544,681		$	5,814,538		-		$	-		$	1,410,215	$	(3,871	)	$	(10,140	)	$	(6,671,273	)	$	539,469
Preference shares converted to common shares (note 6(b)(iii) and (ix))		750,000			750,000		(750,000	)		(750,000	)		-		-			-			-			-			-
Preference shares issued (note 7(b)(ii) and ( viii))		-			-		750,000			750,000			-		-			-			-			750,000
Issued on private placements (note 6 (b)(iv))		29,867			44,800		-			-			-		-			-			-			-			44,800
Issued on private placements (note 7(b)(i))		199,583			299,374		-			-			-		-			-			-			299,374
Fair value of warrants (note 6(c))		-			-		-			-			-		504,043			-			-			-			504,043
Preference shares converted to common shares (note 7(b)(iii) and (ix))		750,000			750,000		(750,000	)		(750,000	)		-		-			-			-			-
Issued on private placements (note 6 (b)(v))		41,206			61,809		-			-			-		-			-			-			-			61,809
Issued on private placements (note 7(b)(iv))		29,867			44,800		-			-			-		-			-			-			44,800
Cancellation of shares (note 6(b)(vi))		(19,269	)		-		-			-			-		-			-			-			-			-
Fair value of warrants (note 7(c))		-			-		-			-			504,043		-			-			-			504,043
Issued on private placements (note 6 (b) (vii))		68,737			103,106		-			-			-		-			-			-			-			103,106
Issued on private placements (note 7 (b)(v))		41,206			61,809		-			-			-		-			-			-			61,809
Fair value of options		-			-		-			-			-		168,730			-			-			-			168,730
Cancellation of shares (note 7(b)(vi))		(19,269	)		-		-			-			-		-			-			-			-
Issued on private placements (note 6(b) (x))		2,300			3,450		-			-			-		-			-			-			-			3,450
Issued on private placements (note 7 (b) (vii))		68,737			103,106		-			-			-		-			-			-			103,106
Comprehensive loss for the year		-			-		-			-			-		-			6,793			(585	)		(1,864,481	)		(1,858,273	)
Fair value of options		-			-		-			-			168,730		-			-			-			168,730
At December 31, 2011		32,617,105		$	7,077,077		-		$	-		$	-	$	2,082,988		$	2,922		$	(10,725	)	$	(8,535,754	)	$	616,508
Issued on private placements (note 7(b) (x))		2,300			3,450		-			-			-		-			-			-			3,450
Comprehensive loss for the year		-			-		-			-			-		6,793			(585	)		(1,864,481	)		(1,858,273	)
At December 31, 2011		32,617,105		$	7,077,077		-		$	-		$	2,082,988	$	2,922		$	(10,725	)	$	(8,535,754	)	$	616,508

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Index

Nerium Biotechnology, Inc.

Interim Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the ~~three~~six month period ended ~~March~~June 3130, 2012

(Unaudited)

		Common Stock				Preferred Stock				Shares to be			Additional Paid in			Accumulated Other Comprehensive			Non- Controlling			Accumulated			Total Stockholders’ Equity
													Accumulated
		Shares		Amount		Shares		Amount		Issued			Capital			Loss			Interest			Deficit
										Additional			Other			Non-						Total
At December 31, 2011			32,617,105	$	7,077,077		-	$	-	$	-		$	2,082,988		$	2,922		$	(10,725	)	$	(8,535,754	)	$	616,508
	Common Stock					Preferred Stock				Paid-in			Comprehensive			Controlling			Accumulated			Stockholders’
Issued on private placements (note 6(b)(xi))			120,071		120,071		-		-		-			-			-			-			-			120,071
	Shares			Amount		Shares		Amount		Capital			Income (Loss)			Interest			Deficit			Equity
Fair value of options (note 7 (iii))			-		-		-		-		-			1,298,290			-			-			-			1,298,290
December 31, 2011			32,617,105	$	7,077,077		-	$	-	$	2,082,988		$	2,922		$	(10,725	)	$	(8,535,754	)	$	616,508
Exercise of options (note 6(b)(xii))			870,000		87,000		-		-		-			-			-			-			-			87,000
Issued on private placements (note 7(b)(xi))			120,071		120,071		-		-		-			-			-			-			120,071
Fair value of options exercised			-		68,262		-		-		-			(68,262	)		-			-			-			-
Fair value of options (note 8 (i), (ii) and (iii))			-		-		-		-		1,382,656			-			-			-			1,382,656
Comprehensive loss for the period			-		-		-		-		-			-			(5,612	)		(179	)		(1,542,353	)		(1,548,144	)
Exercise of options (note 7(b)(xii))			870,000		87,000		-		-		-			-			-			-			87,000
At March 31, 2012			33,607,176	$	7,352,410		-	$	-	$	-		$	3,313,016		$	(2,690	)	$	(10,904	)	$	(10,078,107	)	$	573,725
Fair value of options exercised			-		68,262		-		-		(68,262	)		-			-			-			-
Issued on private placements (note 7(b)(xiii))			120,000		120,000		-		-		-			-			-			-			120,000
Issued on private placements (note 7(b)(xiv))			81,000		81,000		-		-		-			-			-			-			81,000
Shares to be issued on private placements (note 7(b)(xv))			-		-		-		-		325,330			-			-			-			325,330
Comprehensive loss for the period			-		-		-		-		-			(5,609	)		(322	)		(908,444	)		(914,375	)
At June 30, 2012			33,808,176	$	7,553,410		-	$	-	$	3,722,712		$	(2,687	)	$	(11,047	)	$	(9,444,198	)	$	(1,818,190	)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Index

Nerium Biotechnology, Inc.

Interim Condensed Consolidated Statements of Cash Flows

For the ~~three-~~six month ~~period~~periods ended ~~March~~June 3130, 2012 and 2011

(Unaudited)

	March 31 2012			March 31 2011
	June 30 2012			June 30 2011
Cash flow from operating activities
Net loss for the period	$	(1908,~~542,532~~766	)	$	(~~219~~1,~~190~~241,499	)
Items not affecting cash:
Depreciation		919,~~311~~162			1018,~~490~~553
Depreciation included in research and development		37,~~790~~580			37,~~790~~580
Share-based compensation		1,298,290			-
Stock-based compensation		1,382,655			504,043
Earnings from equity investment, net		(226,340	)		-
Changes in non-cash working capital balances:
Accounts receivable		(21,~~348~~915	)		(1,~~032~~961	)
Accounts receivable from related party		(20525,~~000~~100	)		-
Inventory		~~813~~(141,861	)		(38,~~490~~230	)
Prepaid expenses and deposits		(81313,~~253~~005	)		(88150,~~208~~829	)
Accounts payable		~~119~~154,~~590~~045			~~(13~~183,~~321~~360	)
Accrued liabilities		(98180,~~844~~080	)		-
Loan from related party		80,000			-
Employee related payables		14,462			-
Employee related payables		22,325			-
Loan from related party		71,000			-
Customer deposits		440,000			-
Advanced from related party		(3,914	)		-
Advanced from related party		23,236			-
Customer deposits		85,000			-
		252,378			(310,961	)
Income taxes payable		240,000			-
		(323,247	)		(685,061	)
Cash flow from investing activities
Purchase of equipment		-(15,996	)		(46,~~124~~259	)
Prepaid expenses relating to patents		(4,589	)		-
Deposit for equipment		(75,000	)		-
		(4,589	)		(4,124	)
Prepaid expenses relating to patents		(7,794	)		-
		(98,790	)		(6,259	)
Cash flow from financing activities
Issuance of common shares		~~120~~321,071			~~299~~905,~~374~~984
Issuance of preference shares		-			500,000
Common shares to be issued		325,330			-
Proceeds from options exercised		87,000			-
		207,071			799,374
Advances		100,000			-
Effect of exchange rate changes on cash and cash equivalents		(5,159	)		1,230
		833,401			905,984
Increase in cash and cash equivalents		449,701			485,519
Effect of exchange rate changes on cash and cash equivalents		(5,609	)		282
Increase in cash and cash equivalents		405,755			214,946
Cash and cash equivalents, beginning of the period		217,034			186,823
Cash and cash equivalents, end of the period	$	~~666~~622,~~735~~789		$	~~672~~401,~~342~~769
Included in cash and cash equivalents is:
Cash	$	~~438~~327,~~120~~935		$	~~137~~160,~~467~~241
Money market instruments		~~228~~294,~~615~~854			~~534~~241,~~875~~528
	$	~~666~~622,~~735~~789		$	~~672~~401,~~342~~769

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

1.	Basis of Presentation

The accompanying interim condensed consolidated financial statements of Nerium Biotechnology, Inc. and its subsidiaries (the “Company”) have been prepared following generally accepted accounting principles in the United States (“US GAAP”), and are expressed in United States dollars, unless otherwise noted.

Pursuant to the rules and regulations of the Securities and Exchange Commission for Form 10-Q, the interim condensed consolidated financial statements, footnote disclosures and other information normally included in consolidated financial statements prepared in accordance with US GAAP have been condensed or omitted. The interim condensed consolidated financial statements contained in this report are unaudited but, in the opinion of management, reflect all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the interim condensed consolidated financial statements. All significant inter-company accounts and transactions have been eliminated on consolidation. The results of operations for any interim period are not necessarily indicative of results for the full year. The interim condensed consolidated balance sheet at December 31, 2011 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by US GAAP for complete financial statements.

For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Form

10-K for the year ended December 31, 2011.

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management reviews these estimates and assumptions on an ongoing basis using currently available information. Actual results could differ from those estimates.

2.	Going Concern and Economic Dependence

These interim condensed consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next twelve months.

During the three and six month periods ended June 30, 2012, the Company incurred a net income (loss) of $633,766 and ($908,766) respectively. In addition, for the six month period ended June 30, 2012 the Company had negative cash from operations of $323,247. At June 30, 2012 the Company had an accumulated deficit of $9,444,198, cash and cash equivalents of $622,789 and working capital of $1,237,444.

The Company’s profitability during the three month period ended June 30, 2012 is primarily the result of sales to a related party upon which the Company is economically dependent (see note 9).

In order to meet future expenditures and cover administrative costs, the Company may need to raise additional financing. Although the Company has been successful in raising funds to date, and has reported a profit for the first time since inception, there is no assurance that this will continue over the next twelve months. These interim condensed consolidated financial statements do not reflect any adjustments to the carrying values of assets and liabilities that would be necessary if the Company were unable to sustain profitable operations or obtain adequate financing.

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

2. Going Concern

During the three-month period ended March 31, 2012, the Company incurred a net loss of $1,542,532 (three-month period ended March 31, 2011 - $219,190). At March 31, 2012 the Company had an accumulated deficit of $10,078,107, cash and cash equivalents of $666,735 and working capital of $300,332. In order to meet future expenditures and cover administrative costs, the Company will need to raise additional financing. Although the Company has been successful in raising funds to date, there is no assurance that adequate funding will be available in the future, or available under terms favourable to the Company and therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These interim condensed consolidated financial statements do not reflect any adjustments to the carrying values of assets and liabilities that would be necessary if the Company were unable to achieve profitable operations or obtain adequate financing.

3.	Significant Accounting Policies

Adoption of new accounting principles

During the ~~three-~~six month period ended ~~March~~June 3130, 2012 the Company adopted the following Accounting Standards Updates (“ASU”) to the Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (the “ASC”) issued by the FASB.

In May 2011, the FASB issued Accounting Standards Update ("ASU") No. 2011-04—Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in US GAAP and IFRSs ("ASU No. 2011-04"). This authoritative guidance changes the wording used to describe the requirements in US GAAP for measuring fair value and for disclosing information about fair value measurements. ASU No. 2011-04 is effective for interim and annual periods beginning after December 15, 2011. The implementation of this guidance did not have a significant impact on our financial condition, results of operations or cash flows. Refer to note 11 for related disclosures.

In connection with ASU 2011-05, on December 23, 2011, the FASB issued ASU 2011-12 “Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05” an amendment of ASC topic 220 “Comprehensive Income” to allow FASB time to redeliberate whether to present on the face of the financial statements the effects of reclassifications out of accumulated other comprehensive income on the components of net income and other comprehensive income for all periods presented. While FASB is considering this matter, entities should continue to report reclassifications out of accumulated other comprehensive income consistent with the presentation requirements in effect before ASU 2011-05. The ASU is effective for fiscal years, and interim periods, beginning after December 15, 2011. The implementation of this guidance did not have aany ~~significant~~ impact on our financial condition, results of operations or cash flows.

Recently issued accounting pronouncements

On December 16, 2011, the FASB issued ASU No. 2011-11 “Disclosures about Offsetting Assets and Liabilities” an amendment of ASC topic 210 “Balance Sheet.” The objective of this ASU is to improve disclosures about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position. Entities are required to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. This scope would include derivatives, sale and repurchase agreements and reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The objective of this disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of US GAAP and those entities that prepare their financial statements on the basis of IFRS. This ASU is effective for annual periods beginning on or after January 1, 2013, and interim periods within those annual periods. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. ~~The entity is currently evaluating the impact of this pronouncement.~~

Inventory

	June 30 2012		December 31 2011

Raw materials and consumables	$	425,368	$	289,722
Supplies		20,702		47,873
Medicine (finished goods)		64,487		31,101
	$	510,557	$	368,696

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

4. Inventory

	March 31 2012		December 31 2011
Raw materials and consumables	$	293,953	$	289,722
Supplies		22,080		47,873
Medicine (finished goods)		51,850		31,101
	$	367,883	$	368,696

5.	Equipment, net

					March 31 2012		December 31 2011
					June 30 2012		December 31 2011
	Cost		Accumulated Depreciation		Net Book Value		Net Book ~~value~~Value
Lab furniture and equipment	$	270,~~363~~366	$	~~158~~164,~~872~~076	$	~~111~~106,~~491~~290	$	117,275
Clinic, office furniture, and equipment		88,464		61,287		27,177		30,787
Clinic, office furniture and equipment		92,924		64,992		27,932		30,787
Computer equipment		1224,~~990~~979		56,~~684~~629		718,~~306~~350		7,676
Research and development		75,800		2125,~~477~~267		5450,~~323~~533		58,113
	$	~~447~~464,~~617~~069	$	~~247~~260,~~320~~964	$	~~200~~203,~~297~~105	$	213,851

6. ~~Capital~~Equity ~~Stock~~Investment

Nerium Biotechnology, Inc. owns a wholly-owned subsidiary, Nerium SkinCare, Inc. (“NSC”), a Texas corporation, which owns a 30% residual interest in Nerium International, LLC (“NI”). Actual ~~Authorized~~income distributions range from 20% to 30% depending on the nature of products sold. No distributions have been received to June 30, 2012.

Unlimited Preferred stock, non-voting, issuable in series

	June 30 2012

Carrying value of investment at December 31, 2011	$	-
Reversal of investment impairment to original cost		300
Income from equity investment to June 30, 2012		305,981
Less: elimination of downstream sales (note 9)		(79,941	)
Carrying value of investment at June 30, 2012	$	226,340

~~(b)~~Summarized ~~Issued~~unaudited financial data of NI for the three and six month periods ended June 30:

Common stock	Shares			Amount
	Three months ended June 30						Six months ending June 30
As at December 31, 2010		31,544,681		$	5,814,538
		2012			2011			2012		2011
Private placement (i)		199,583			299,374
Revenue	$	14,309,151		$	23		$	19,455,106	$	23
Preference share conversion (iii)		500,000			500,000
Gross profit (loss)	$	4,026,286		$	(44	)	$	5,137,189	$	(44	)
Private placement (iv)		29,867			44,800
Income (loss) from continuing operations	$	2,055,828		$	(325,233	)	$	2,385,816	$	(325,233	)
Private placement (v)		41,206			61,809
Net income (loss)	$	2,055,828		$	(325,233	)	$	2,385,816	$	(325,233	)
Cancellation of shares (vi)		(19,269	)		-
Private placement (vii)		68,737			103,106
Preference share conversion (ix)		250,000			250,000
Private placement (x)		2,300			3,450
As at December 31, 2011		32,617,105			7,077,077
Private placement (xi)		120,071			120,071
Stock option exercise (xii)		870,000			87,000
Fair value of options exercised		-			68,262
As at March 31, 2012		33,607,176		$	7,352,410

Preferred stock	Shares			Amount
As at December 31, 2010		-		$	-
Issuance of preference shares (ii)		500,000			500,000
Conversion to common shares (iii)		(500,000	)		(500,000	)
Issuance of preference shares (viii)		250,000			250,000
Conversion to common shares (ix)		(250,000	)		(250,000	)
As at December 31, 2011 and March 31, 2012				$	-

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

67. Capital Stock ~~- continued~~

(b) Issued - continued

(a) Authorized
Unlimited Common stock
Unlimited Preferred stock, non-voting, issuable in series
(b) Issued
Common stock	Shares			Amount

As at December 31, 2010		31,544,681		$	5,814,538
Private placement (i)		199,583			299,374
Preference share conversion (iii)		500,000			500,000
Private placement (iv)		29,867			44,800
Private placement (v)		41,206			61,809
Cancellation of shares (vi)		(19,269	)		-
Private placement (vii)		68,737			103,106
Preference share conversion (ix)		250,000			250,000
Private placement (x)		2,300			3,450
As at December 31, 2011		32,617,105			7,077,077
Private placement (xi)		120,071			120,071
Stock option exercise (xii)		870,000			87,000
Fair value of options exercised		-			68,262
Private placement (xiii)		120,000			120,000
Private placement (xiv)		81,000			81,000
As at June 30, 2012		33,808,176		$	7,553,410

Preferred stock	Shares			Amount
As at December 31, 2010	-		$	-
Issuance of preference shares (ii)	500,000			500,000
Conversion to common shares (iii)	(500,000	)		(500,000	)
Issuance of preference shares (viii)	250,000			250,000
Conversion to common shares (ix)	(250,000	)		(250,000	)
As at December 31, 2011 and June 30, 2012	-		$	-

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2012 (Unaudited)

7.	Capital Stock – continued

(b)

Issued

(i)

On March 29, 2011, the Company completed the fourth closing of its non-brokered private placement by issuing 199,583 common shares at $1.50 per share for gross proceeds of $299,374.

(ii)

On March 9, 2011, the Company completed a non-brokered private placement to issue 500,000 Series “A” Convertible Preference Shares, at a subscription price of $1.00 per share for a total of $500,000. The Convertible Preference Shares are non-voting, non-redeemable, non-retractable and are not entitled to receive dividends. Each Series “A” Convertible Preference Share may, at the option of the holder, be converted into one common share. The expiry date of the conversion is December 31, 2012.

(iii)

On May 5, 2011 the 500,000 Series “A” Convertible Preference Shares were converted into 500,000 common shares.

(iv)

On May 5, 2011, the Company completed the fifth closing of its non-brokered private placement by issuing 29,867 common shares at $1.50 per share for gross proceeds of $44,800.

(v)

On June 28, 2011, the Company completed the sixth closing of its non-brokered private placement by issuing 41,206 common shares at $1.50 per share for gross proceeds of $61,809.

(vi)

On June 28, 2011 the Company cancelled 19,269 residual shares as result of the shares in trust being distributed to individual shareholders.

(vii) On September 8, 2011 and September 29, 2011, the Company completed the seventh and eighth closing of its non-brokered private placement by issuing 58,737 and 10,000 common shares at $1.50 per share for gross proceeds of $88103,106 ~~and $15,000, respectively~~.

(viii)

On September 26, 2011, the Company approved a non-brokered private placement to issue 1,000,000 Series “B” Convertible Preference Shares, at a subscription price of $1.00. The Convertible Preference Shares are non-voting, non-redeemable, non-retractable and are not entitled to receive dividends. Each Series “B” Convertible Preference Share may, at the option of the holder, be converted into one common share. The expiry date of the conversion is December 31, 2012. Pursuant to this private placement 250,000 preference shares were issued.

(ix)

On September 29, 2011, the 250,000 Series “B” Convertible Preference Shares were converted into 250,000 common shares.

(x)

On December 22, 2011, the Company completed the ninth closing of its non-brokered private placement by issuing 2,300 common shares at $1.50 per share for gross proceeds of $3,450.

(xi)

In February 2012, the Company's Board of Directors approved a private placement of up to 2,000,000 common shares of the Company at a subscription price of $1.00 per common share. On March 30, 2012, the Company completed the first closing of its non-brokered private placement by issuing 120,071 common shares at $1.00 per share for gross proceeds of $120,071.

(xii)

During the quarter ended March 31, 2012, 870,000 stock options were exercised at $0.10 per option for gross proceeds of $87,000. The fair value of the options was $68,262.

11(xiii) On April 25, 2012, the Company completed the second closing of its non-brokered private placement by issuing 120,000 common shares at $1.00 per share for gross proceeds of $120,000.

(xiv)

On May 10, 2012, the Company completed the third closing of its non-brokered private placement by issuing 81,000 common shares at $1.00 per share for gross proceeds of $81,000.

(xv)

During June 2012, the Company received gross proceeds of $325,330 for 325,330 common shares at $1.00 per share pursuant to its fourth non-brokered private placement. These shares were issued on July 27, 2012 (note 15).

(xvi)

On June 14, 2012, an investor advanced $100,000 to the Company as partial payment for shares to be issued at a future date.

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

67. Capital Stock - continued

(c)

Warrants

A summary of the Company’s warrant activity is as follows:

	March 31, 2012					December 31, 2011
	June 30, 2012					December 31, 2011
	Number of Warrants			Exercise Price		Number of Warrants			Exercise Price
Outstanding, beginning		500,000		$	1.25		500,000		$	1.25
Expired		-			-		(500,000	)		1.25
Expired (i)		(500,000	)		1.25		(500,000	)		1.25
Issued		-			-		500,000			1.25
Outstanding, ending		~~500,000~~-		$	~~1.25~~-		500,000		$	1.25

~~The~~(i) ~~fair~~On ~~value~~May of5, 2012, the 500,000 warrants ~~issued in May 2010 was $161,476~~expired. The fair value of the warrants was estimated using the Black-Scholes pricing model based on the following assumptions: risk-free interest of 1.89%, volatility of 143%; expected dividend yield of 0% and expected life of one year.

~~On May 5, 2011, the 500,000 warrants expired; and replacement warrants were issued on May 6, 2011 with the same terms and an expiry date of May 5, 2012~~8. ~~The~~ ~~fair value of the 500,000 warrants was $504,043 and was expensed. The fair value of the warrants was estimated using the Black~~Stock-~~Scholes~~Based ~~pricing model based on the following assumptions: risk-free interest of 1.65%; volatility of 181%; expected dividend yield of 0% and expected life of one year.~~Compensation

7The Company has reserved and set aside up to 6,256,000 common shares for the granting of options to directors, officers, employees and consultants. On ~~Stock-Based~~June ~~Compensation~~22, 2012, the plan was replaced by two plans. In one plan the Company has reserved 3,128,000 common shares for the granting of options to employees, and in the second plan the Company has reserved 3,128,000 common shares for the granting of options to directors, officers and consultants. The terms of the awards under both plans are determined by the Board of Directors.

~~The~~A ~~Company~~summary ~~has~~of ~~reserved~~the ~~and~~status ~~set~~of ~~aside~~the upCompany's tooutstanding ~~6,256,000~~stock ~~common~~options ~~shares~~as ~~for~~of ~~the~~June ~~granting~~30, of2012 ~~options~~and toDecember ~~directors~~31, ~~officers~~2011, ~~employees~~ and ~~consultants. The~~changes ~~terms~~during of the ~~awards~~periods ~~under~~is ~~the~~presented ~~Plan~~in ~~are determined by~~ the ~~Board~~following ~~of Directors~~table.

A summary of the status of the Company's outstanding stock options as of March 31, 2012 and December 31, 2011, and changes during the periods is presented in the following table.

	June 30, 2012						December 31, 2011
	Stock Options			Weighted- average exercise price			Stock options		Weighted- average exercise price
Outstanding, beginning		3,630,000		$	0.47			3,180,000	$	0.47
Exercised (i)		(870,000	)		(0.10	)
Granted (ii) and (iii)		150,000			1.50			450,000		1.50
Expired		-			-			-		-
Outstanding, ending		2,910,000		$	0.79			3,630,000	$	0.47

	March 31, 2012						December 31, 2011
	Stock Options			Weighted- average exercise price			Stock options		Weighted- average exercise price
Outstanding, beginning		3,630,000		$	0.47			3,180,000	$	0.47
Exercised (i)		(870,000	)		(0.10	)		-		-
Granted (ii) and (iii)		150,000			1.50			450,000		1.50
Expired		-			-			-		-
Outstanding, ending		2,910,000		$	0.79			3,630,000	$	0.47

Index

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2012 (Unaudited)

7. Stock-Based Compensation- continued

The weighted-average remaining contractual life and weighted-average exercise price of options outstanding and of options exercisable as at March 31, 2012 are as follows:

		Options Outstanding		Options Exercisable
			Weighted
		Weighted-	- Average		Weighted-
		Average	Remaining		Average
Exercise		Exercise	Contractual		Exercise
Prices	Outstanding	Price	Life	Exercisable	Price
	#		Years	#
CDN$0.10	750,000	CDN $0.10	2.80	750,000	CDN$0.10
CDN$0.50	800,000	CDN $0.50	0.27	800,000	CDN$0.50
CDN$1.22	310,000	CDN $1.22	1.29	310,000	CDN$1.22
$1.22	450,000	$1.22	3.41	450,000	$1.22
$1.50	600,000	$1.50	4.29	150,000	$1.50
	2,910,000	$0.79	2.34	2,460,000	$0.66

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

78. ~~Share~~Stock-Based Compensation - continued

~~(i) 1,950,000 stock options with an exercise price of CDN$0.10 were granted to various directors, employees and consultants on January 17, 2007, which vested immediately and expire January 17, 2012.~~ The ~~fair value was determined to be $153,000 at $0.08 per option, using the Black~~weighted-~~Scholes~~average ~~model~~remaining ~~for~~contractual ~~pricing~~life ~~options.~~and ~~This amount was recorded as stock~~weighted-~~based~~average ~~compensation~~exercise ~~expense~~price ~~and an increase to accumulated paid in capital. The following assumptions were used: risk free interest rate~~ of ~~return~~options ofoutstanding ~~4.3%, expected stock volatility of 105%, dividend yield of 0%~~ and ~~expected life~~ of ~~5 years. In January 2012, 870,000 of these~~ options ~~were~~exercisable ~~exercised~~as ~~for~~at ~~$87,000.~~June ~~The fair value of these options was $68~~30,~~262.~~ ~~On January 17,~~ 2012 ~~the~~are remaining un-exercised options were amended to expire January 17, 2015. The fair value of the amended options is $1,084,251 at $1.45 per option, using the Black-Scholes model for pricing options. The following assumptions were used: risk free interest rate of return of 1.06%, expected stock volatility of 148%, dividend yield of 0% and expected life of 3 years. This amount was recorded as ~~stock-based compensation expense and an increase to accumulated paid in capital.~~follows:

(ii) 450,000 stock options were granted to certain employees on June 27, 2011 with an exercise price of $1.50, which vest 25% on June 27, 2012; 25% on June 27, 2013; 25% on June 27, 2014 and 25% on June 27, 2015 and expire June 27, 2016. The fair value was determined to be $647,925 at $1.44 per option, using the Black-Scholes model for pricing options. $84,365 was recorded as an increase to stock-based compensation expense and an increase to accumulated paid in capital for the three-month period ended March 31, 2012. The following assumptions were used: risk free interest rate of return of 2.79%; expected volatility of 181%; dividend yield of 0% and expected life of 5 years.

Options Outstanding						Options Exercisable
Exercise Prices	Outstanding		Weighted‑ Average Exercise Price	Weighted‑ Average Remaining Contractual Life		Exercisable		Weighted‑ Average Exercise Price
	#		Years			#

CDN$0.10		750,000	CDN $0.10		2.55		750,000	CDN$0.10
CDN$0.50		800,000	CDN $0.50		0.02		800,000	CDN$0.50
CDN$1.22		310,000	CDN $1.22		1.04		310,000	CDN$1.22
$1.22		450,000	$1.22		3.16		450,000	$1.22
$1.50		600,000	$1.50		4.04		262,500	$1.50

		2,910,000	$0.79		2.10		2,572,500	$0.70

(~~iii~~i) ~~150~~1,950,000 stock options with an exercise price of CDN$0.10 were granted to avarious ~~consultant~~directors, employees and consultants on ~~February~~January 1417, 2007, which vested immediately and expire January 17, 2012. ~~with~~The fair value was determined to be $153,000 at $0.08 per option, using the Black-Scholes model for pricing options. This amount was recorded as stock-based compensation expense and an ~~exercise~~increase ~~price~~to accumulated paid in capital. The following assumptions were used: risk free interest rate of $1return of 4.503%, ~~which~~expected ~~vest~~stock ~~immediately~~volatility of 105%, dividend yield of 0% and expected life of 5 years. In January 2012, 870,000 of these options were exercised for $87,000. The fair value of these options was ~~determined~~$68,262. On January 17, 2012 the remaining un-exercised options were amended to beexpire January 17, 2015. The fair value of the amended options is $~~129~~1,~~674~~084,252 at $01.8645 per option, using the Black-Scholes model for pricing options. The following assumptions were used: risk free interest rate of return of 1.4406%;, expected stock volatility of 148%;, dividend yield of 0% and expected life of 53 years. This amount was recorded as stock-based compensation expense and an increase to accumulated paid in capital.

8(ii) 450,000 stock options were granted to certain employees on June 27, 2011 with an exercise price of $1.50, ~~Related~~which ~~Party~~vest ~~Transactions~~25% on June 27, 2012; 25% on June 27, 2013; 25% on June 27, 2014 and ~~Balances~~25% on June 27, 2015 and expire June 27, 2016. The fair value was determined to be $647,925 at $1.44 per option, using the Black-Scholes model for pricing options. $84,365 and $168,730 was recorded as an increase to stock-based compensation expense and an increase to accumulated paid in capital for the three-month and six-month period ended June 30, 2012 respectively. The following assumptions were used: risk free interest rate of return of 2.79%; expected volatility of 181%; dividend yield of 0% and expected life of 5 years.

~~During~~(iii) ~~the~~150,000 ~~three-month~~stock ~~period~~options ~~ended~~were ~~March~~granted 31to a consultant on February 14, 2012 with an exercise price of $1.50, ~~the~~which ~~Company~~vest ~~entered~~immediately ~~into~~and expire on August 29, 2016. The fair value was determined to be $129,674 at $0.86 per option, using the Black-Scholes model for pricing options. The following ~~related~~assumptions ~~party~~were ~~transactions~~used: risk free interest rate of return of 1.44%; expected volatility of 148%; dividend yield of 0% and expected life of 5 years.

The Company incurred consulting fees of $nil (three-month period ended March 31, 2011 - $15,000) during the three-month period ended March 31, 2012, for services provided by a director of the Company. This amount is included in general and administrative expenses.

In the three-month period ended March 31, 2012, total sales by the Company to Nerium International, LLC (“NI”) was $683,340 (three-month period ended March 31, 2011 - $nil). The unrealized profit of $27,150 associated with these sales to the related party has been eliminated (sales of $97,876 less cost of sales of $70,726). As of March 31, 2012, the Company’s $300 investment in NI has been recorded at $nil as a result of accumulated losses to date of $88,688 (December 31, 2011 - $271,325).

As at March 31, 2012, accounts receivable from NI was $20,000 (December 31, 2011 - $nil).

At March 31, 2012, the loan from related party relates to a loan from the chief executive officer totalling $80,000 (December 31, 2011 - $nil). The loan is unsecured, non-interest bearing and due on demand.

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

9. ~~Commitments~~Related Party Transactions and Balances

During the three and six month periods ended June 30, 2012, the Company entered into the following related party transactions:

The Company incurred consulting fees of $15,000 for the three and six month periods ended June 30, 2012 (three and six month periods ended June 30, 2011 - $15,000 and $30,000 respectively), for services provided by a director of the Company. This amount is included in general and administrative expenses.

In the three and six month periods ended June 30, 2012, total sales by the Company to NI was $2,506,559 and $3,189,899 respectively (three and six month period ended June 30, 2011 - $nil). The unrealized profit of $79,941 associated with these sales to the related party has been eliminated (note 6).

As at June 30, 2012, accounts receivable from NI was $525,100 (December 31, 2011 - $nil).

At June 30, 2012, the loan from related party relates to a loan from the chief executive officer totalling $71,000 (December 31, 2011 - $nil). The loan is unsecured, non-interest bearing and due on demand.

10.	Commitments

Operating leases

At ~~March~~June 3130, 2012, the Company was committed to operating lease payments for its various premises in the following amounts:

2012	$	~~163~~187,~~166~~584
2013		~~220~~376,~~094~~532
2014		~~199~~378,~~686~~417
2015		~~196~~350,~~691~~530
	$	779,637
2016		330,000
Thereafter		1,815,000
	$	3,438,063

In addition, the Company is committed to the following:

(a) The Company has entered into two separate agreements with one individual. The first agreement, a production and purchasing agreement effective June 2004, entitles the individual to receive $3.25 per vial of Anvirzel sold to third parties in exchange for the use of facilities and production supervision. The second agreement, a consulting agreement effective January 2007, entitles the individual to receive an additional $3.25 per vial of Anvirzel sold to third parties in exchange for consulting services in relation to the production of Anvirzel. Both agreements remain in effect for as long as Anvirzel is produced in Honduras. The commissions paid are not significant and are included in cost of sales.

(b) Prior to 2004, the Company entered into a consulting agreement which entitles the consultant to receive $1.00 per vial of Anvirzel sold to third parties in Central America and $2.00 per vial for patients coming from countries other than Central America, to a maximum of $20,000 per month, expiring in 2018. The commissions paid are not significant and are included in cost of sales.

(c) During 2011, the Company entered into a consulting agreement which entitles the consultant to receive a 5% commission, based on a per unit price charged on each product produced for commercial sale to the end consumer, that was formulated by the consultant. The agreement expires in 2031. The commission incurred is $29,896 and $40,664 for the three-month and six-month period ended June 30, 2012 respectively and are included in cost of sales.

~~The~~(d) ~~commissions~~During ~~paid~~June ~~are~~2012, ~~not~~the ~~significant~~Company ~~and~~committed ~~are~~to ~~included~~purchase inequipment ~~cost~~totalling $147,500 for which a deposit of ~~sales~~$75,000 was recorded as at June 30, 2012.

~~10. Financial Instruments~~15

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2012 (Unaudited)

11.	Financial Instruments

Fair value

The Company's financial instruments include cash and cash equivalents, accounts receivable, ~~and~~accounts receivable from related party, accounts payables, accrued liabilities, ~~and~~advances, employee related payables, ~~and~~ loan from related party and customer deposits. The carrying value of the financial instruments approximates their fair value because of the short-term maturities of these items.

The Company's risk exposure and the impact on its financial instruments are summarized below:

Credit risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its contractual obligations. The Company is exposed to credit risk on its cash and cash equivalents, accounts receivable and accounts receivable from related party.

The Company has deposited the cash and cash equivalents with reputable financial institutions, from which management believes the risk of loss is minimal. The Company's cash and cash equivalents are not subject to any external restrictions.

15Credit risk exists in that a significant majority of the Company’s receivables is concentrated to one related party. The Company’s management considers this to be a low risk given the related party nature of the balance and the payment history of the related party to date.

Index

Notes to the Interim Condensed Consolidated Financial Statements

March 31, 2012 (Unaudited)

10. Financial Instruments - continued

Liquidity risk

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at June 30, 2012 the Company held cash and cash equivalents of $622,789 and has positive working capital of $1,237,444. The Company does not have any long-term debt ~~other than accrued liabilities~~. The Company also has commitments discussed in Note 910.

~~Since~~Although ~~inception,~~ the Company has ~~financed~~been ~~its~~successful ~~liquidity~~in ~~needs~~raising ~~through~~funds ~~private~~to ~~placements~~date, ofand ~~preferred~~has ~~and~~reported ~~common~~profit ~~stock. To~~for ~~secure~~the ~~additional~~first ~~capital~~time since inception, ~~the~~there ~~Company~~is no assurance that this will ~~attempt~~continue toover the next twelve months and the Company may raise additional funds through the issuance of common stock or similar equity instruments if required.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market interest rates.

The Company is exposed to interest rate risk arising from fluctuations in interest rates received on its cash and cash equivalents. Fluctuations in market interest rates do not have a significant impact on the Company's results of operations due to the short-term nature of interest bearing cash and cash equivalents.

Currency risk

The Company is exposed to currency fluctuations as a significant amount of its accrued liabilities are denominated in Canadian dollars and Honduran Lempira totalling $63,785 and $11,545 respectively in US dollars. The Company does not use derivative instruments to reduce its exposure to foreign currency risk.

1112. Capital ~~Disclosure~~Management

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to maintain its ongoing operations. The Company includes ~~stockholder~~stockholders’s equity in the definition of capital.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

There were no changes to the Company's approach to capital management during three- and six month ~~period~~periods ended ~~March~~June 3130, 2012. The Company is not subject to externally imposed capital requirements.

Index

Nerium Biotechnology, Inc.

Notes to the Interim Condensed Consolidated Financial Statements

~~March~~June 3130, 2012 (Unaudited)

1213. Segmented Information

The Company uses a management approach for determining segments. The management approach designates the internal organization that is used by management for making operating decisions and assessing performance as the source of the Company’s reportable segments. The Company’s management reporting structure provides for only one segment: healthcare.

The regions and countries in which the Company had identifiable assets and revenues are presented in the following table. Identifiable assets are those that can be directly associated with a geographic area.

As at March 31, 2012	United States			Honduras			Total
As at June 30, 2012	United States			Honduras			Total
Equipment	$	6676,~~515~~311		$	~~133~~126,~~782~~794		$	~~200~~203,~~297~~105
Total assets	$	12,~~191~~359,~~609~~677		$	~~313~~284,~~418~~020		$	12,~~505~~643,~~027~~697
Six month period ended June 30, 2012	United States			Honduras			Total
Revenues	$	2,981,560		$	190,490		$	3,172,050
Net income (loss) for the period	$	(863,643	)	$	(45,123	)	$	(908,766	)
Three month period ended June 30, 2012	United States			Honduras			Total
Revenues	$	2,395,676		$	87,081		$	2,482,757
Net income (loss) for the period	$	664,421		$	(30,655	)	$	633,766
As at December 31, 2011	United States			Honduras			Total
Equipment	$	72,421		$	141,430		$	213,851
Total assets	$	655,065		$	306,438		$	961,503
Six month period ended June 30, 2011	United States			Honduras			Total
Revenues	$	-		$	229,001		$	229,001
Net loss for the period	$	(1,260,027	)	$	18,528		$	(1,241,499	)
Three month period ended June 30, 2011	United States			Honduras			Total
Revenues	$	-		$	104,216		$	104,216
Net loss for the period	$	(1,037,389	)	$	15,080		$	(1,022,309	)

Three-month period ended March 31, 2012	United States			Honduras			Total
Revenues	$	585,884		$	103,409		$	689,293
Net loss for the period	$	(1,528,064	)	$	(14,468	)	$	(1,542,532	)

As at December 31, 2011	United States		Honduras		Total
Equipment	$	72,421	$	141,430	$	213,851
Total assets	$	655,065	$	306,438	$	961,503

Three-month period ended March 31, 2011	United States			Honduras		Total
Revenues	$	-		$	124,785	$	124,785
Net loss for the period	$	(222,638	)	$	3,448	$	(219,190	)

13. Subsequent Events

On April 25, 2012, the Company completed the second closing of its non-brokered private placement by issuing 120,000 common shares at $1.00 per share for gross proceeds of $120,000.

On May 10, 2012, the Company completed the third closing of its non-brokered private placement by issuing 81,000 common shares at $1.00 per share for gross proceeds of $81,000.

Index

~~Item~~Nerium 2Biotechnology, Inc.~~Management’s~~ ~~Interim Discussion and Analysis of Financial Condition and Results of Operations~~

Notes to the Interim Condensed Consolidated Financial Statements

June 30, 2012 (Unaudited)

14.	Income Taxes

NSC is a US company and it is subject to US income tax at an estimated rate of 35%. During the six month period ended June 30, 2012, NSC has net income of approximately $1,375,000, which would result in taxes payable of approximately $480,000.

Management is currently in the process of exploring certain tax planning opportunities which may allow, among other things, to offset the Company’s prior year loss carryforwards against the taxable income of NSC, resulting in no taxes payable. Due to the uncertainty of the results of these tax planning measures, the Company has established a tax provision of $240,000 as at June 30, 2012, which represents the midpoint of the range of possible outcomes as determined by management.

15.	Subsequent Events

On July 9, 2012, 800,000 stock options were exercised at $0.50 per option for gross proceeds of $400,000. The fair value of the options was $315,000.

On July 20, 2012, the Company completed the fourth closing of its non-brokered private placement by issuing 386,626 common shares for $1.00 for gross proceeds of $386,626, which includes the $325,330 that the Company received prior to June 30, 2012 (note 7(b)(xv)).

On August 15, 2012, the Company completed the fifth closing of its non-brokered private placement by issuing 161,612 common shares for $1.00 for gross proceeds of $161,612.

Index

Nerium Biotechnology, Inc.

Item 2.

Management’s Interim Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Statements

Statements made in this Form 10-Q that are not historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate,” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbor processes for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. Except as required by law, we disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

All references herein to the terms “we,” “our,” “us,” “Nerium,” and “the Company” refer to Nerium Biotechnology, Inc. and its subsidiaries.

Overview

Nerium Biotechnology, Inc. (“Nerium” or the “Company”) is a biotechnology company involved in the development of Nerium oleander-based products for the treatment of certain forms of proliferative diseases and viral infections. We are also involved in the development of a skincare/cosmetic line of products based on the patent pending aloe-oleander extract. Our existing product line includes Anvirzel™, HIviral, HEP-viral, and NeriumAD.

Nerium was incorporated pursuant to the Canada Business Corporations Act on June 1, 2006 to acquire Phoenix Biotech, LTD (Phoenix BVI), a British Virgin Islands corporation, and its five majority-owned Latin American subsidiaries, from Phoenix Biotechnology, Inc., a Texas corporation (Phoenix US). Nerium currently owns, indirectly, four Latin American corporations, collectively known as “The Salud Integral Group”, located in Honduras and El Salvador, which integrate the manufacturing, marketing, and sales of our treatment products, while the cosmetic line is being developed by the wholly owned subsidiary, Nerium SkinCare, Inc.

Nerium utilizes a proprietary method to grind the Nerium oleander plant cuttings into the biomass used for manufacturing of its products. Drogueria Salud Integral, one of the subsidiaries within the “Salud Integral Group”, has a manufacturing facility in Tegucigalpa, Honduras, that operates under Honduran “current Good Manufacturing Practices” (cGMP) standards and is inspected by the Honduran health ministry to confirm compliance with such standards. Drogueria Salud Integral is located inside the pharmaceutical manufacturing plant of Francelia Laboratories, whose cGMP clean room is fully operational and is currently producing our existing line of treatment products. Through its Latin American subsidiaries, our drug products are available to international patients who import them under personal use exemption rules of their respective countries.

Anvirzel™, our lead product, is intended to treat certain forms of cancer, and has successfully completed a United States Food and Drug Administration Phase I Study which was limited to establishing safety and dosage. The study was conducted at the Cleveland Clinic in Cleveland, Ohio.

In addition to Anvirzel™, Nerium currently has three other marketable products, HIviral, HEP-viral and NeriumAD. HIviral is for use as an adjuvant therapy in the treatment of HIV/AIDS, HEP-viral is for use as an adjuvant therapy in the treatment of hepatitis C and NeriumAD is a skin cream for age-defying treatment.

NeriumAD is manufactured by a third party company in Texas and marketed by Nerium International, LLC (“NI”) based in Dallas, TX.

1819

Index

Nerium Biotechnology, Inc.

Anvirzel™ is available as a prescription drug through the Salud Integral Clinic in Honduras. While it has historically been administered by intramuscular injection (IM), many users are now administering it sublingually (“SL”) by placing drops under the tongue. The SL method of administration may soon be clinically tested as we received, on April 29, 2012, an approval from the US FDA to commence a Phase 1 study of the combination of Carboplatin, Docetaxel and increasing doses of sublingual Anvirzel in advanced non-small cell lung cancer patients at MD Anderson Cancer Center in Houston, Texas. A successful Phase 1 may result in a better understanding of the bioavailability of Anvirzel when administered sublingually. The success of the study could also lead to a multi-site Phase II clinical study.

Anvirzel is currently provided in a 10ml vial as 150mg of freeze-dried oleander extract powder that is reconstituted with 10ml of water. In the proposed clinical study, Sublingual Anvirzel will be provided in a 30ml vial as 300mg of freeze-dried oleander extract powder. We believe that in the future Anvirzel may be provided in a quick dissolving strip or tablet which can be placed under the tongue in order to make administration more user friendly than it presently is.

HIviral and HEP-viral are provided in a 30ml vial as 300mg of freeze-dried oleander extract powder that is reconstituted with 20ml of water. No further development of either product is planned until after completion of the proposed cancer study. HIviral is for use as an adjuvant therapy in the treatment of HIV/AIDS and HEP-viral is for use as an adjuvant therapy in the treatment of hepatitis C.

NeriumAD is a cosmetic product designed for use on wrinkled and/or aging skin. It has been developed by Nerium SkinCare, Inc. It is anticipated that additional skincare type products will be developed.

Results of Operations ~~– Three months Ended March 31, 2012 Compared to March 31, 2011~~

~~Sales~~Three ~~for~~Months ~~the~~Ended ~~three~~June ~~months ended March 31~~30, 2012 ~~increased~~Compared ~~by $565,192, or 461.2%~~ to ~~$687,734~~Three ~~from~~Months ~~$122,542~~Ended ~~for~~June ~~the three-month period ended March 31~~30, 2011. This increase can be attributed to the increase in sales of $585,464 by NSC. Sales of other Nerium products decreased by $20,272 for the three months ended March 31, 2012 from the corresponding period of the prior year.

~~Other~~Sales ~~income comprises income from administrative services performed by our Honduran subsidiary. Other income~~ for the three months ended ~~March~~June 3130, 2012 ~~decreased~~increased by $~~684~~2,375,814 ~~or 43.9%~~ to 1$$2,~~559~~ 478,932 from $2103,~~243~~118 for the three~~-month~~ ~~period~~months ~~ended~~June ~~March 31~~30, 2011. This ~~decrease~~increase ~~resulted~~is ~~from~~attributable ~~fewer~~to ~~billed~~the ~~record~~increase ~~keeping~~in ~~services~~the sale of skin care products by Nerium SkinCare, Inc.

~~Cost~~Other ofincome ~~sales~~ for the three months ended ~~March~~June 3130, 2012 ~~increased~~totaled by $~~430~~3,~~965~~825, oran ~~1,106.9%~~increase toof $~~469~~2,~~900 from $38~~727,~~935~~ ~~for~~or ~~the three-month period ended March 31, 2011~~2. ~~This~~48% ~~increase~~from ~~is attributed to~~ the ~~increase~~$1,098 ~~in sales by NSC. Our gross margin~~ for the three months ended ~~March~~June 3130, ~~2012 was 31~~2011.7% ~~compared~~Other toincome ~~68.2%~~consists ~~for the corresponding period~~ of ~~the~~administrative ~~prior~~services ~~year.~~billed ~~This~~by ~~decrease~~our subsidiary in ~~margins resulted from fewer sales of Anvirzel as a percentage of the total and the advent of the sale of skin care products.~~Honduras

~~Stock-based~~Cost ~~compensation~~of ~~expense~~sales for the ~~quarter~~three months ended ~~March~~June 3130, 2012 totaled $1,~~298~~457,~~290~~094, ~~compared~~an toincrease of $~~nil~~1,437,170 from the $19,924 for the corresponding period of the prior year. In ~~addition,~~This increase resulted from an increase in the ~~750~~sale of skin care products by Nerium SkinCare,~~000~~ ~~remaining~~Inc. ~~outstanding~~Our ~~options~~gross ~~from~~profit margin for the ~~2007~~three ~~grant~~months ~~were~~ended ~~amended~~June ~~and~~30, ~~extended~~2012 was 41.4% compared to 81.7% for anthe ~~additional~~corresponding ~~three~~period ~~years~~of atthe anprior ~~exercise~~year. ~~price~~The decrease in the gross profit margin resulted from fewer sales of $0Anvirzel as a percentage of the total and sharp increase in the sale of skin care products.~~10.~~

General and administrative expenses for the three months ended ~~March~~June 3130, 2012 ~~increased~~totaled by$331,170, a decrease of $~~159~~35,~~795~~268, or 699.6% ~~to $389,468~~ from the $~~229~~366,~~673~~438 for the ~~three-month~~corresponding period ~~ended~~of ~~March~~the ~~31,~~prior ~~2011~~year. This ~~increase~~decrease isresulted ~~attributed~~from toa ~~the~~decrease ~~additional~~in ~~expenses~~payroll ~~associated~~which ~~with~~was ~~the~~partially ~~lauch~~off-set ofby ~~the~~an ~~skin~~increase ~~care~~in ~~line~~professional fees.

Research and development expenses ~~totaled $64,856~~ for the three~~-month~~ ~~period~~months ended ~~March~~June 3130, 2012 totaled $32,788, ~~consistent~~a ~~with~~decrease of $193,246, or 85.5% from the $62226,~~138~~034 for the ~~three-month~~corresponding period ~~ended~~of ~~March~~the ~~31,~~prior ~~2011~~year. This decrease resulted from a general reduction in research as the company switched its efforts to skin care.

~~Depreciation~~Stock ~~expense~~based ~~totaled~~compensation ~~$9,311~~ for the three~~-month~~ ~~period~~months ended ~~March~~June 3130, 2012, ~~slightly~~totaled ~~less~~$84,365, ~~than~~a ~~the~~decrease of $10419,~~490~~678, ~~for~~or ~~three-month~~83.3% from the corresponding period ~~ended~~of ~~March~~the ~~31,~~prior ~~2011~~year. The decrease resulted from ~~additional~~the ~~items~~issuance ~~being~~of ~~fully~~fewer ~~depreciated~~options.

~~The~~Depreciation ~~loss on foreign exchange~~ for the three~~-month~~ ~~period~~months ended ~~March~~June 3130, 2012 totaled $~~nil~~9,851, ~~compared~~an toincrease of $21,~~739~~788, ~~for~~or 22.2% from the corresponding period of the prior year.. ~~This~~The ~~zero~~increase ~~loss~~in ~~for~~depreciation ~~the three months ended March 31, 2012~~ resulted from ~~the~~an USincrease ~~Dollar~~in ~~and~~depreciable ~~the~~assets, ~~Canadian~~particularly ~~dollar~~furniture ~~being~~and ~~at par for most of the quarter~~equipment.

19For the three months ended June 30, 2012, the company had a loss on foreign currency exchange of $296 compared to a gain on foreign currency of $2,023 for the corresponding period of the prior year. Foreign currency gains and losses resulted from changes in the value of the US dollar against the currencies of Honduras and Canada.

As a result of the foregoing, the company had net income before income taxes of $873,766 for the three months ended June 30, 2012 compared to a loss of $1,021,703 for the corresponding period of the prior year. For the three months ended June 30, 2012, the company had an income tax liability of $240,000, making the net income $$633,766. There was no provision for income taxes for the corresponding period of the prior year.

Index

AsNerium ~~a result of the forgoing~~Biotechnology, ~~we incurred a loss for the three-month period ended March 31, 2012 of $1,542,532 ($0~~Inc.05 ~~per share) compared to a loss for the 2011 three-month period of $219,190 ($0.01 per share). Most of this increase can be attributed to the stock-based compensation.~~

WeFor ~~had a gain on~~ the ~~exchange~~three ~~loss~~months onended ~~translating~~June ~~foreign~~30, ~~operations~~2012 ~~for~~there ~~the~~was ~~three-month~~an ~~period~~exchange ~~ended~~difference ~~March~~on ~~31,~~translating ~~2012~~foreign operations of $~~5,612~~3. ~~compared~~This tocompares awith ~~gain of~~ $~~6,683~~606 infor the ~~three-month~~corresponding period ~~ended~~of ~~March~~the ~~31,~~prior ~~2011~~year. ~~The~~ ~~difference~~These isdifferences a result because of ~~the~~ exchange ofdifferentials between the Honduran Lempira against the US ~~Dollar~~dollar.

AsFor athe ~~result~~three ofmonths ~~the~~ended ~~forgoing~~June 30, we2012, ~~incurred~~there was a ~~comprehensive~~ loss ofattributable ~~$1,548,144~~to ~~for the three~~non-~~month~~controlling ~~period~~interest ~~ended~~of ~~March~~$143. ~~31,~~This ~~2012~~compares ~~compared~~ to a$141 ~~comprehensive loss~~ for the ~~three-month~~corresponding period ~~ended~~of ~~March~~the ~~31,~~prior ~~2011 of $212,507~~year.

WeAs ~~had~~ a ~~loss~~result of the foregoing, the net income attributable to ~~non-~~the controlling interest ~~of $179~~ for the three~~-month~~ ~~period~~months ended ~~March~~June 3130, 2012 was $633,912, or $0.02 per share compared to a loss ~~attributable~~of to$1,021,562 ~~non-controlling~~or ~~interest~~$(0.03) ofper ~~$145~~share infor the ~~same~~corresponding period inof ~~2011~~the prior year.

Six Months Ended June 30, 2012 Compared to Six Months Ended June 30, 2011

Sales for the six months ended June 30, 2012 increased by $2,941,006 to $3,166,666 from $225,660 for the six month period ended June 30, 2011. This increase can be attributed to net sales totaling $2,981,560 for the six month period by NSC. Sales of other Nerium products totaled $185,106 for the six month period ended June 30, 2012.

Other income comprises income from administrative services performed by our Honduran subsidiary. Other income for the six month period ended June 30, 2012 increased by $2,043 to $5,384 from $3,341 for six month period ended June 30, 2011. This increase resulted from billed record keeping services.

Cost of sales for six month period ended June 30, 2012 increased by $1,868,135 to $1,926,994 from $58,859 for the six month period ended June 30, 2011. This increase is attributed to the increase in sales by NSC. Our gross margin for the six months ended June 30, 2012 was 39.3% compared to 74.3% for the corresponding period of the prior year. This decrease in margins resulted from fewer sales of Anvirzel as a percentage of the total and the advent of the sale of skin care products.

Stock-based compensation expense for the six month period ended June 30, 2012 totaled $1,382,655 compared to $504,043 for the corresponding period of the prior year. In the current period $1,084,252 represents the amended value of the 750,000 options which expiry date was extended to January 17, 2015; $168,730 for the 450,000 stock options granted to certain employees on June 27, 2011 and $129,674 which represents the fair value of 150,000 options granted to a consultant.

General and administrative expenses for the six month period ended June 30, 2012 increased by $124,527 to $720,638 from $596,111 for the six month period ended June 30, 2011. This increase is attributed to the additional expenses associated with the launch of the skin-care line.

Research and development expenses totaled $97,644 for six month period ended June 30, 2012, which is a decrease of $190,528 from $288,172 for the six month period ended June 30, 2011. The Company focused on the production and sales of the skincare line in the six month period ended June 30, 2012.

Depreciation expense totaled $19,162 for six month period ended June 30, 2012, slightly more than the $18,553 for the six-month period ended June 30, 2011. The increase resulted from additional items being depreciated in the current period due to additions of furniture and equipment.

The gain on foreign exchange six month period ended June 30, 2012 totaled $296 compared to a loss of $4,762 for the corresponding period of the prior year. This minimal loss for the six month period ended June 30, 2012 resulted from the US Dollar and the Canadian dollar being at par for most of the period.

As a result of the forgoing, we incurred an loss for the six month period ended June 30, 2012 of $908,766 ($0.03 per share) compared to a loss for the 2011 six month period of $1,241,499 ($0.04 per share). Most of this decrease can be attributed to the sales of skincare products in NSC.

We had a loss on the exchange on translating foreign operations for the six month period ended June 30, 2012 of $5,609 compared to a gain of $7,289 in the six month period ended June 30, 2011. The difference is a result of the exchange of the Honduran Lempira against the US Dollar.

Index

Nerium Biotechnology, Inc.

As a result of the above, we incurred a comprehensive loss of $914,375 for the six month period ended June 30, 2012 compared to a comprehensive loss for the six month period ended June 30, 2011 of $1,234,210.

We had a loss attributable to non-controlling interest of $322 for the six month period ended June 30, 2012 compared to a loss attributable to non-controlling interest of $286 in the same period in 2011.

Summary of Quarterly Results

The following table sets forth selected results of operations for our eight most recently completed quarters.

Quarter Ended	Accounting Policies	Total Revenues ($)		Net Income (Loss) ($)			Basic and Diluted Net Loss Per Common Share
June 30, 2012	US GAAP	$	2,482,757		633,766		$	0.02
March 31, 2012	US GAAP		689,293		(1,542,532	)	$	(0.05	)
December 31, 2011	US GAAP		133,980		(210,795	)	$	(0.01	)
September 30, 2011	IFRS		489,421		(412,772	)	$	(0.01	)
June 30, 2011	IFRS		104,216		(1,022,309	)	$	(0.03	)
March 31, 2011	IFRS		124,785		(219,190	)	$	(0.01	)
December 31, 2010	Canadian GAAP		88,780		(369,143	)	$	(0.01	)
September 30, 2010	Canadian GAAP		93,311		(800,361	)	$	(0.03	)

We have experienced an increase in revenues in the second quarter (“Q2”) in 2012 compared to Q2 2011 by $2,378,541. During the last half of 2011, NI launched its skin care line, which is formulated and sold by our wholly owned subsidiary, NSC. Also, a stronger demand for Anvirzel was reflected in an increase in the number of units sold while at a lower average price per unit.

Loss per quarter has been in the range of $219,190 in the first quarter (“Q1”) of 2011 to the Q1 of 2012 quarter high of $1,542,532. These losses fluctuate primarily due to research and development expenditures and share-based compensation charges. A share-based compensation charge in third quarter (“Q3”) of 2010 was $508,500, $300,079 in the Q3 of 2011 and $504,043 in Q2 of 2011. It was $nil in the other quarters of 2010, and the Q1 of 2011. Due to the large increase in sales in Q2 2012, we experienced net income at $633,766.

Liquidity

As at ~~March~~June 3130, 2012 we had cash and cash equivalents of $~~666~~622,~~735~~789 and working capital of $~~300~~1,~~332~~237,444. This compares with cash and cash equivalents of $217,034 and working capital of $334,150 as of December 31, 2011. Most cash equivalents are held in a money market fund, earning a variable rate of market interest, at Texas Capital Bank. The balance of cash equivalents are held in various operating accounts at Texas Capital Bank, Banco Ficohsa (located in Honduras) and Banco Credomatic (located in Honduras).

Historically, ~~the~~we ~~Company~~have ~~has~~generated ~~generate~~ the cash required for operations, as well as ~~its~~ research projects, through the private placement issuances of common shares. During the ~~three~~six month period ended ~~March~~June 3130, 2012 ~~the~~we ~~Company~~ received $~~120~~321,071 in cash from the sale of ~~120~~321,071 shares of ~~its~~ common stock and 870,000 stock options were exercised at $0.10 for gross proceeds of $87,000.

Based upon prior year operations, ~~the~~we ~~Company~~had ~~has~~ insufficient cash flow to fund ~~its~~our operation and to execute ~~its~~our business plan for the next twelve months. However, revenue for the ~~three~~six ~~months~~month period ended ~~March~~June 3130, 2012 has ~~nearly~~far exceeded that of the entire year 2011. This growth is expected to continue, and when combined with anticipated sales of common stock, should provide the funds necessary to allow ~~the~~us ~~Company~~ to execute its business plan for the next twelve months. ~~However, if the Company is unable to sustain this revenue growth and/or sell shares at a sufficient price, it will be unable to continue as a going concern.~~

Index

Nerium Biotechnology, Inc.

Capital Resources

We had no long-term debt financing arrangements and do not anticipate incurring any such debt. Since incorporation, a majority of cash has been raised through private placement issuances of common shares. It is expected that further cash will be raised through the private placement of common shares, which, along with cash received through continuing product sales, will be sufficient to meet capital requirements for 2012. However, given the uncertain state of the capital markets, we have developed a contingency plan in the event that we are unable to generate ~~cash~~such ~~through~~a ~~the~~level ~~sale~~ of ~~equity~~cash, which plan includes the scaling back of certain research and development projects. There were no commitments for capital expenditures as at ~~March~~June 3130, 2012.

Off Balance Sheet Arrangements

As at the date of this filing, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of the Company, including, and without limitation, such considerations as liquidity and capital resources.

Index

Commitments

Operating leases

At ~~March~~June 3130, 2012, we committed to operating lease payments for its various premises in the following amounts:

2012	$	~~163~~187,~~166~~584
2013		~~220~~376,~~094~~532
2014		~~199~~378,~~686~~417
2015		~~196~~350,~~691~~530
	$	779,637
2016		330,000
Thereafter		1,815,000
	$	3,438,063

~~In addition, we committed to the following:~~23

(a) We entered into two separate agreements with one individual. The first agreement, a production and purchasing agreement effective June 2004, entitles the individual to receive $3.25 per vial of Anvirzel sold to third parties in exchange for the use of facilities and production supervision. The second agreement, a consulting agreement effective January 2007, entitles the individual to receive an additional $3.25 per vial of Anvirzel sold to third parties in exchange for consulting services in relation to the production of Anvirzel. Both agreements remain in effect for as long as Anvirzel is produced in Honduras.Index

~~(b)~~Nerium ~~Prior to 2004~~Biotechnology, ~~we entered into a consulting agreement which entitles the consultant to receive $1~~Inc.00 ~~per vial of Anvirzel sold to third parties in Central America and $2.00 per vial for patients coming from countries other than Central America, to a maximum of $20,000 per month, expiring in 2018.~~

~~(c)~~In ~~During 2011~~addition, ~~the~~we ~~Company~~are ~~entered~~committed ~~into a consulting agreement which entitles the consultant~~ to ~~receive 5% commission, based on a per unit price charged on each product produced for commercial sale to~~ the ~~end consumer, that was formulated by the consultant. The agreement expires in 2031~~following:

(b)

Prior to 2004, the Company entered into a consulting agreement which entitles the consultant to receive $1.00 per vial of Anvirzel sold to third parties in Central America and $2.00 per vial for patients coming from countries other than Central America, to a maximum of $20,000 per month, expiring in 2018. The commissions paid are not significant and are included in cost of sales.

(c)

During 2011, the Company entered into a consulting agreement which entitles the consultant to receive a 5% commission, based on a per unit price charged on each product produced for commercial sale to the end consumer, that was formulated by the consultant. The agreement expires in 2031. The commission incurred is $29,896 and $40,664 for the three-month and six-month period ended June 30, 2012 respectively and are included in cost of sales.

(d)

During June 2012, the Company committed to purchase equipment totalling $147,500 for which a deposit of $75,000 was recorded as at June 30, 2012.

Disclosure Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to provide reasonable assurance that all relevant information is gathered and reported to senior management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), on a timely basis so that appropriate decisions can be made regarding public disclosure. Management of the Company, with the participation of the CEO and CFO, has evaluated the effectiveness of the Company’s disclosure controls and procedures as at ~~March~~June 3130, 2012, as required by Canadian securities law. Based on that evaluation, the CEO and CFO have concluded that, as at ~~March~~June 3130, 2012, the disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in the Company’s annual filings and interim filings (as such terms are defined under Multilateral Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings) and other reports filed or submitted under Canadian securities laws were recorded, processed, summarized and reported within the time period specified by those laws and that material information was accumulated and communicated to management of the Company, including the CEO and CFO, as appropriate to allow for accurate disclosure to be made on a timely basis.

Internal Controls over Financial Reporting

Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with US GAAP. The CEO and CFO have concluded that there has been no change in the Company’s internal control over financial reporting during the three-month period ended ~~March~~June 3130, 2012 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. As of ~~March~~June 3130, 2012, the Company’s internal control over financial reporting was effective.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no disclosures as our stock does not trade.

2124

Index

~~Item~~Nerium 4Biotechnology, Inc.~~Controls~~ ~~and Procedures~~

Item 4.

Controls and Procedures

(a)	Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, we are responsible for conducting an evaluation of the effectiveness of the design and operation of our internal controls and procedures, as defined in rules 13a-15(e) under the Securities Exchange Act of 1934, as of the end of the fiscal year covered by this report. Disclosure controls and procedures means that the material information required to be included in our Securities and Exchange Commission (“SEC”) reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, including any consolidating subsidiaries, and was made known to us by others within those entities, particularly during the period when this report was being prepared. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were effective as of ~~March~~June 3130, 2012.

Management’s Annual Report on Internal Control over Financial Reporting

As of ~~March~~June 3130, 2012, management assessed the effectiveness of our internal control over financial reporting. The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is defined in rule 13a-15(f) or 15d-15(f) promulgated under the Securities and Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company’s Chief Executive Officer and Chief Financial Officer and effected by the Company’s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with US GAAP ~~in the United States of America~~ and includes those policies and procedures that:

(i) Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of our assets;

(ii) Provide reasonable assurance our transactions are recorded as necessary to permit preparation of our financial statements in accordance with US GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

(iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statement.

In evaluating the effectiveness of our internal control over financial reporting, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control – Integrated Framework. Based on that evaluation, completed by Dennis R. Knocke, our President and Chief Executive Officer, and Joseph B. Nester, our Chief Financial Officer, management concluded that, during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below.

This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board was inadequate segregation of duties consistent with control objectives. The aforementioned material weakness was identified by our President and Chief Executive Officer, and our Chief Financial Officer, in connection with the review of our interim condensed consolidated financial statements as of ~~March~~June 3130, 2012.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the three- and six month ~~period~~periods ended ~~March~~June 3130, 2012 that have materially affected, or that are reasonably likely to materially affect, the Company’s internal control over financial reporting.

2225

Index

Nerium Biotechnology, Inc.

Limitations on the effectiveness of controls

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparations and presentations. Also projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Part II

Item 1. Legal Proceedings

As of ~~May~~August 1427, 2012, we had no outstanding legal proceedings.

Item 1A. Risk Factors

Going Concern Opinion

Under United States reporting standards the Company’s auditors issue a going concern footnote to the annual audited financial statement.

Anvirzel™ is Not a Cure for Cancer

Anvirzel™ is not a cure for cancer. Anvirzel™ may or may not have the desired effect of inhibiting the growth of tumors or causing the elimination or reduction of tumors. Effectiveness has not been demonstrated in clinical trials.

Lack of Approval in Major North American Markets

While Anvirzel™ has been approved for sale by the health ministry in Honduras (through the issuance of a Sanitary Register), neither Health Canada nor the USFDA have approved Anvirzel™ for use in Canada or the United States, respectively.

Outside of individual use, the granting of which is at the discretion of the respective agencies, sales of Anvirzel™ in the United States and Canada is limited, the result of which will be limited revenue from major North American markets. We have no regulatory exemptions in either the US or Canada.

While we intend to seek Health Canada and USFDA approval for some of its developmental stage products, there can be no assurance that such approval will ever be granted. Failure to receive such approval may have a material impact on revenue generation by the Company.

Use of Cardiac Glycosides May Cause Unwanted Side Effects

Possible side effects that may be associated with the administration of a cardiac glycoside, such as Anvirzel™, include allergic reaction, nausea, vomiting and atrioventricular block. Such potential side effects may deter some patients from undergoing treatment with Anvirzel™. The Company is not aware of any reports of life-threatening side-effects associated with the use of Anvirzel™.

Combining Therapeutic Dosages of Different Cardiac Glycoside Could Be Dangerous

Cardiac glycosides are well known to be toxic to humans. Overdosing of cardiac glycosides can lead to cardiac arrhythmia, cardiac toxicity and death. Anvirzel™ contains cardiac glycosides in sub-therapeutic amounts. Clinical testing on humans and animals has demonstrated Anvirzel™ and its cardiac glycoside components are below toxic levels and are safe. However, when used in combination with other cardiac glycosides (such as digoxin) for congestive heart failure, Anvirzel™ may have a toxic effect due to the patient exceeding the maximum tolerated dosage for cardiac glycosides.

Positive Immune Response Not Independently Proven

Positive immune response after treatment with our antiviral drugs is based on evidence gathered from internal clinical trials and has not been verified by independent third parties. A positive immune response does not equal a cure. There is no evidence that oleandrin has cured, or has the ability to cure, any viral-related diseases. The Company does not claim that use of the antiviral drugs will cause a positive immune response.

2326

Index

Nerium Biotechnology, Inc.

Lack of Physician Acceptance

Physician education and acceptance of a medical product in the major markets is limited to scientific journals, news media, and experience with treating patients that have chosen to add alternative treatment to their therapies until a product is approved in their respective countries. As Anvirzel™ has not been approved by either Health Canada or the USFDA, the ability for the Company to educate physicians as to the potential benefits of Anvirzel™ may be limited.

The Company’s Products, including Anvirzel™, May Become Obsolete

The biotechnology industry has been characterized by the frequent introduction of new products. Accordingly, we may be adversely affected by the new products and technology developed by ~~its~~our competitors. In addition, as the potential benefits of oleander extract enter the public domain, our competitors may seek to develop, on an expedited basis, products which compete with our products.

GENERAL RISK FACTORS

An investment in securities of the Company should be considered highly speculative due to the nature of our business and its stage of development and should be considered only by investors who can afford the total loss of their investment.

An investment in securities of the Company involves a significant degree of risk. The risks related to the Company and its business includes the following:

Marketability

There is no market for the common shares and shareholders may not be able to resell them.

Necessity for Additional Capital

WeAlthough we have ~~limited~~been ~~cash~~successful ~~and~~in ~~revenues.~~raising Wefunds ~~may~~to ~~need~~date, toand ~~raise~~we ~~further~~haev ~~capital~~reported ~~through~~profit for the ~~sale~~first oftime ~~additional~~since ~~equity~~inception, ~~capital~~there tois no assurance that this will continue toover ~~implement~~the ~~our~~next ~~business~~twelve ~~plan.~~months Weand ~~anticipate~~we ~~the~~may need ~~for~~to raise additional ~~capital~~funds tothrough ~~fully~~the ~~implement~~issuance ~~our~~of ~~business~~common ~~plan~~stock ~~over~~or ~~the~~similar ~~next~~equity ~~twelve~~instruments ~~months~~if required.

Speculative Nature of Securities

There is no assurance that we will be successful in implementing our business plan. We have limited funds available for it and one source of ~~significant~~ future funds presently available to us is through the sale of equity capital. The shares of the Company are speculative.

Currency Risk

We are exposed to currency risk as a part of the Subsidiaries' business is carried out in Honduran Lempira and we maintain Honduran Lempira denominated bank accounts but use ~~U.S.~~US dollars as our reporting currency. Unfavorable changes in the exchange rate between Honduran Lempira and ~~U.S.~~US dollars may materially affect the foreign exchange gain/losses. We do not use derivative instruments to reduce our exposure to foreign currency risk.

Reliance on Key Personnel

Our success depends, in large part, upon the continuing contributions of its key technical, marketing, sales and management personnel. The loss of the service of several key people within a short period of time could have a material adverse effect upon our financial condition and operations. Our future success is also dependent upon its continuing ability to attract and retain other highly qualified personnel. Competition for such personnel is intense, and our inability to attract and retain additional key employees could have a material adverse effect on our financial condition and operations.

Dependence on Ability to Obtain Technical and Administrative Staff

We anticipate that we will require more administrative, executive, scientific, engineering and manufacturing employees. We have no binding arrangements to fulfill our staffing requirements and there is no assurance we will be able to successfully accomplish this requirement. If the Company is not able to do so, it will diminish the Company’s ability to operate effectively.

The Company Operates in a Competitive Market Sector

The medical, drug and biotechnology businesses are highly competitive. The Company and its products will be competing with various other manufacturers with existing technological support and acceptance in the same markets the Company will target. Many of these other products are well-established, have substantial sales volume, and are produced and marketed by companies with much greater financial resources, facilities, organization and experience than the Company. If the potential benefits of oleander extract enter the public domain, competitive companies with substantially more resources than the Company may try to develop products competitive with the Company’s products.

2427

Index

Nerium Biotechnology, Inc.

Intellectual Property Protection may be Uncertain

In respect of certain of its proprietary rights, the Company may need to secure licenses from third parties and/or assignments of rights from independent contractors. This is particularly applicable to intellectual property which may arise under sponsored research agreements with public universities. While no licensing agreements have been entered in to to-date, there is no assurance that the Company will secure the necessary licenses or assignments to execute on its business plan. The loss of any proprietary rights which may be protected or protectable under any of the foregoing future intellectual property safeguards may result in the loss of a competitive advantage over present or potential competitors.

The Company has registered the mark Anvirzel™ in certain jurisdictions in Latin America and the Caribbean and plans to apply for additional protection as funds allow, but does not have the rights to use the mark in the United States and Canada. Neither the Company nor its licensors have registered all of its trademarks or copyrights. The Company may decide not to take additional steps to secure its rights in certain copyrights, trademarks and/or patents to which it may be entitled. Failure to do so, in the case of copyrights and trademarks, may reduce the access of the Company to the courts, and to certain remedies of statutory damages and attorneys’ fees, to which it may be entitled in the event of a violation of the Company’s proprietary and intellectual rights by third parties. Similarly, the failure to seek protections of any patentable materials to which the Company may be entitled may result in loss of patent protection should a third party copy the patentable technology or process.

The loss of any proprietary rights which are protectable under any of the foregoing intellectual property safeguards may result in the loss of a competitive advantage over present or potential competitors, with a resulting decrease in the profitability for the Company. There is no guarantee that such a loss of competitive advantage could be remedied or overcome by the Company at a price which the Company would be willing or able to pay.

There has not been any action brought against the Company alleging intellectual property violations.

High Start-up and Operating Risks During Initial Operations

The Company incurred start-up losses during its development period and initial period of operations and will experience lower revenues and operating margins than an established company until the customer base grows to a more optimal operating level. There can be no assurance that we will be able to achieve satisfactory operating results within the expected period of time or develop and have in operation sufficient level of employees to operate the facility.

The Company May Not Be Able to Successfully Develop its Current Product Line

Although the Company believes that its products can be profitably developed and manufactured, there may be unanticipated technological, regulatory and marketing issues that may make the products unfeasible to produce or to market. In addition, delays in the production and release testing of Anvirzel™ in the Company’s pharmaceutical clean room facilities can occur due to unforeseen development obstacles, some of which are beyond the Company’s control. If the Company is unable to complete the products as planned, its revenue and earnings growth could be materially adversely affected.

Index

Nerium Biotechnology, Inc.

Failure of Promotional Activities

Although there are certain expectations with respect to the projected results of promotion activities, particular promotions may not reach anticipated levels of success. If early advertising and promotion is not successful, the likelihood of the Company expending all of its funds prior to the Company reaching a level of profitability will be increased.

The Company May Be Unable to Manage Rapid Growth

The Company’s business plan will, if successfully implemented, result in the rapid expansion of its business on a widespread basis. Rapid expansion of the Company’s operations may place a significant strain on the Company’s management, financial and other resources. The ability to manage future growth will depend upon the Company’s ability to monitor operations, control costs, maintain regulatory compliance, maintain effective quality controls and significantly expand internal management and technical, information and accounting systems, and to attract, assimilate and retain additional qualified personnel.

The Company Does Not Carry Product Liability Insurance

Insurance carriers are currently reluctant to provide product liability insurance for biotechnology products due to the limited claims history for such products. The Company has no plans to obtain such insurance ~~and~~for ~~may~~products besold ~~unable~~by toNSC ~~secure product liability insurance~~only, orbut benot ~~unable~~for toproducts ~~secure~~sold ~~such~~by ~~insurance~~the ~~except~~Salud onIntegral ~~terms unacceptable to the Company~~Group. In the event of major product liability litigation or a major award against the Company during a time when the Company has no available insurance, the Company may sustain significant losses of its operating capital.

Index

The Company is Subject to Extensive Regulation

The healthcare industry is subject to extensive regulation relating to licensure, conduct of operations, ownership of facilities, addition of facilities and services and prices for services. Currently, the Company and many of its patients rely on regulatory guidance applicable to individual use importation of Anvirzel.

Each jurisdiction in which the Company may operate has its own regulatory scheme addressing the development, testing, labeling, manufacturing, registration, notification, clearance or approval, marketing, distribution, record-keeping and reporting requirements for human drugs.

While the Company currently has a Sanitary Register issued by the Ministry of Health of the Republic of Honduras for the manufacture, sale and distribution of Anvirzel™, HIviral and HEP-viral, as well as approvals for sale and distribution in the Republics of El Salvador and Guatemala for Anvirzel™, there can be no assurances that the Sanitary Register will be extended. Rules and regulations governing the sales of pharmaceuticals are subject to the laws of the issuing countries, as well as the terms and conditions of international treaties. Given that the Company’s pharmaceutical operations take place only in Honduras, the Sanitary Register only shows approval under Honduran regulations for manufacturing, sale, and distribution in Honduras. Additional regulatory approval may be required for some or all products developed by the Company if the Company expands operations to other jurisdictions. Failure to achieve initial approval will require modification and redesign of the Company’s products or, at worst, elimination of the product. The Company may not have the financial resources to modify its products or implement new designs.

Rules and regulations governing the sales of pharmaceuticals are subject to the laws of the issuing countries, as well as the terms and conditions of international treaties. Given that the Company’s pharmaceutical operations take place only in Honduras, the Sanitary Register only shows approval under Honduran regulations for manufacturing, sale, and distribution in Honduras. Additional regulatory approval may be required for some or all products developed by the Company if the Company expands operations to other jurisdictions. Failure to achieve initial approval will require modification and redesign of the Company’s products or, at worst, elimination of the product. The Company may not have the financial resources to modify its products or implement new designs.

Risks Applicable to Selling Products in Foreign Countries

Sales of products in foreign countries expose the Company to certain risks, including the difficulty and expense of maintaining foreign sales distribution channels, barriers to trade, potential fluctuations in foreign currency exchange rates, political and economic instability, availability of suitable export financing, accounts receivable collections, tariff regulations, foreign taxes, export licensing requirements and other foreign regulations that may apply to the export of its products. In addition, the Company may experience difficulties in providing prompt and cost-effective service of its products in foreign countries.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the ~~three~~six months ended ~~March~~June 3130, 2012, ~~the~~we ~~Company~~ issued ~~121~~321,~~071~~701 shares of ~~its~~our common stock for $~~121~~321,701 ~~070~~ and exercised 870,000 warrants at $.10 per share for $87,000. We also received $325,330 gross proceeds for 325,330 common shares that were issued July 27, 2012. The $~~208~~646,~~071~~401 received is ~~being~~ used for general working capital.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

~~Item 5.Other Information~~29

None

Index

~~Item~~Nerium 6Biotechnology, Inc.~~Exhibits~~

Item 5.

Other Information

None

Item 6.

Exhibits

Exhibit No.	Name of Exhibit

31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
32.1	Certifications pursuant to Securities Exchange Act of 1934 Rule13a-14(b) or 15d-14(b) and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. SecSection 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NERIUM BIOTECHNOLOGY, INC By: /s/ Dennis R. Knocke Dennis R. Knocke President and Chief Executive Officer

ByDated: ~~/s/~~August ~~Dennis~~27, ~~R. Knocke Dennis R. Knocke President and Chief Executive Officer~~2012

Dated: May 14, 2012

	By:	/s/ Joseph B. Nester
		Joseph B. Nester
		Vice-President, Chief Financial Officer

Dated: ~~May~~August 1427, 2012

2730

Filing Compare · NERIUM BIOTECHNOLOGY INC